Whoopi Goldberg and The View co-hosts reveal their GLP-1 weight loss journeys

Three co-hosts of The View—Whoopi Goldberg, Joy Behar, and Sunny Hostin—have openly discussed their use of GLP-1 medications for weight loss. These drugs, including Mounjaro and Ozempic, have grown in popularity as demand for effective weight management solutions rises. Each has shared personal reasons for turning to the treatments, from health concerns to post-surgery recovery.

Whoopi Goldberg revealed she once weighed nearly 300 pounds but now feels confident about her appearance. After back surgery left her on steroids, she turned to Mounjaro to restart her metabolism. The medication helped her shed weight, though she did not disclose exact figures.

Sunny Hostin also used Mounjaro, losing weight and lowering her cholesterol. She had felt ashamed after gaining weight during the COVID-19 pandemic and was alarmed when her cholesterol reached 200. The drug improved both her weight and her health markers.

Joy Behar lost 25 pounds with the help of a GLP-1 medication, though she did not name which one. Her experience reflects a broader trend: since 2023, sales of these drugs have exploded. The market grew from around $20 billion in 2023 to over $50 billion by 2025, fueled by high demand. Shortages occurred in 2024 due to manufacturing limits, but production expanded by early 2026 as companies like Novo Nordisk and Eli Lilly increased supply.

The three women's experiences highlight the growing reliance on GLP-1 drugs for weight loss and health improvements. With the market now stabilizing after shortages, access to these medications has become easier. Their stories add to the ongoing discussion about the role of pharmaceutical treatments in managing weight and metabolic health.